{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-000708","form_type":"8-K","ticker":null,"cik":"0001840904","company_name":"ATAI Life Sciences N.V.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.223167+00:00","generated_at":"2026-05-28T05:34:08.482334+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"atai appoints Srinivas Rao as sole CEO, Gerd Kochendoerfer as COO, promotes Kevin Craig to CMO and Glenn Short to CSO","bullets":["Dr. Srinivas Rao becomes sole CEO effective Jan 1, 2025, after co-CEO transition.","Gerd Kochendoerfer appointed COO effective Dec 3, 2024, from NFlection Therapeutics.","Kevin Craig promoted to CMO leading VLS-01 and EMP-01 Phase 2 trials; Glenn Short named CSO.","VLS-01 now screening patients; Phase 2b data for BPL-003 (Beckley Psytech) expected mid-2025.","Dr. Rao receives $629,200 base salary, 55% bonus target, and option for 2.34M shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-000708","json":"https://secwatch.observer/filing/0001140361-25-000708.json","markdown":"https://secwatch.observer/filing/0001140361-25-000708.md","text":"https://secwatch.observer/filing/0001140361-25-000708.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125000708/0001140361-25-000708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125000708/ef20040004_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:34:08.482334+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"071713e79d","claim":"Srinivas Rao was appointed as Chief Executive Officer at ATAI Life Sciences N.V..","evidence_excerpt":"Dr. Srinivas Rao will serve as the Company’s sole Chief Executive Officer and principal executive officer, effective January 1, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125000708/0001140361-25-000708-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"112b0a277d","claim":"Florian Brand departed as Co-Chief Executive Officer at ATAI Life Sciences N.V..","evidence_excerpt":"Florian Brand stepped down as Co-Chief Executive Officer and member of the Company’s management board as of December 31, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125000708/0001140361-25-000708-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Co-Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"d3345a75f7","claim":"Gerd Kochendoerfer was appointed as Chief Operating Officer at ATAI Life Sciences N.V..","evidence_excerpt":"the Board appointed Dr. Gerd Kochendoerfer as the Company’s Chief Operating Officer, effective December 3, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036125000708/0001140361-25-000708-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}